Charmacy Pharmaceutical Co (HKSE:02289) Beneish M-Score: -2.79 (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02289 Charmacy Pharmaceutical Co Ltd HKSE:02289
76 GF Score
Price HK$5.50
GF Value HK$8.38
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Charmacy Pharmaceutical Co Beneish M-Score?

Charmacy Pharmaceutical Co HKSE:02289 76 Beneish M-Score is -2.79 as of Aug. 21, 2026. GuruFocus rates HKSE:02289 with a GF Score™ of 76/100 and a GF Value™ of HK$8.38 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 116 Medical Distribution companies, Charmacy Pharmaceutical Co ranks better than 77.59% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.79 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Charmacy Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

HKSE:02289' s Beneish M-Score Range Over the Past 10 Years
Min: -2.87   Med: -2.42   Max: -2.02
Current: -2.79

During the past 12 years, the highest Beneish M-Score of Charmacy Pharmaceutical Co was -2.02. The lowest was -2.87. And the median was -2.42.


Charmacy Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Charmacy Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Charmacy Pharmaceutical Co Beneish M-Score Chart

Charmacy Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.37 -2.44 -2.34 -2.40 -2.79

Charmacy Pharmaceutical Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.34 0.00 -2.40 0.00 -2.79

HKSE:02289 vs MCK, COR, CAH: Beneish M-Score Comparison

For the Medical Distribution subindustry, Charmacy Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Charmacy Pharmaceutical Co Beneish M-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Charmacy Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Charmacy Pharmaceutical Co's Beneish M-Score falls into.


HKSE:02289
76GF Score
Charmacy Pharmaceutical Co Ltd HKSE:02289
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Charmacy Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Charmacy Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0405+0.528 * 0.9446+0.404 * 0.8364+0.892 * 1.0228+0.115 * 0.9447
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9367+4.679 * -0.056722-0.327 * 1.0285
=-2.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was HK$1,408 Mil.
Revenue was HK$4,844 Mil.
Gross Profit was HK$375 Mil.
Total Current Assets was HK$3,934 Mil.
Total Assets was HK$4,375 Mil.
Property, Plant and Equipment(Net PPE) was HK$325 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$38 Mil.
Selling, General, & Admin. Expense(SGA) was HK$35 Mil.
Total Current Liabilities was HK$3,625 Mil.
Long-Term Debt & Capital Lease Obligation was HK$69 Mil.
Net Income was HK$51 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$299 Mil.
Total Receivables was HK$1,323 Mil.
Revenue was HK$4,736 Mil.
Gross Profit was HK$347 Mil.
Total Current Assets was HK$3,235 Mil.
Total Assets was HK$3,691 Mil.
Property, Plant and Equipment(Net PPE) was HK$339 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$37 Mil.
Selling, General, & Admin. Expense(SGA) was HK$36 Mil.
Total Current Liabilities was HK$2,977 Mil.
Long-Term Debt & Capital Lease Obligation was HK$52 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1407.589 / 4843.813) / (1322.547 / 4735.618)
=0.290595 / 0.279277
=1.0405

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(346.74 / 4735.618) / (375.475 / 4843.813)
=0.07322 / 0.077516
=0.9446

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3933.863 + 325.421) / 4374.72) / (1 - (3235.039 + 339.095) / 3690.562)
=0.026387 / 0.031547
=0.8364

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4843.813 / 4735.618
=1.0228

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(37.485 / (37.485 + 339.095)) / (38.326 / (38.326 + 325.421))
=0.099541 / 0.105364
=0.9447

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(34.748 / 4843.813) / (36.268 / 4735.618)
=0.007174 / 0.007659
=0.9367

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((68.832 + 3624.771) / 4374.72) / ((52.286 + 2977.314) / 3690.562)
=0.844306 / 0.820905
=1.0285

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(51.119 - 0 - 299.263) / 4374.72
=-0.056722

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Charmacy Pharmaceutical Co has a M-score of -2.79 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.79 mean?
Charmacy Pharmaceutical Co (HKSE:02289) has a Beneish M-Score of -2.79 as of Aug. 21, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Charmacy Pharmaceutical Co and its competitors. According to the industry distribution chart, Charmacy Pharmaceutical Co ranks #26 out of 116 companies in the Medical Distribution industry, placing it in the top 22.4%.
Is Charmacy Pharmaceutical Co's Beneish M-Score too high?
Charmacy Pharmaceutical Co's current Beneish M-Score is -2.79. Based on the distribution chart, Charmacy Pharmaceutical Co ranks #26 out of 116 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Charmacy Pharmaceutical Co has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Charmacy Pharmaceutical Co's Beneish M-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Charmacy Pharmaceutical Co ranks #26 out of 116 companies for Beneish M-Score. This places Charmacy Pharmaceutical Co in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Distribution company?
A good Beneish M-Score depends on the Medical Distribution industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Charmacy Pharmaceutical Co and its competitors. Charmacy Pharmaceutical Co's current Beneish M-Score is -2.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charmacy Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Charmacy Pharmaceutical Co (HKSE:02289) is currently considered Possible Value Trap. The stock's GF Value™ is HK$8.38, compared to a current price of HK$5.50 — trading 34.4% below its estimated fair value. The current Beneish M-Score is -2.79. Charmacy Pharmaceutical Co's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Charmacy Pharmaceutical Co (HKSE:02289), the current Beneish M-Score is -2.79 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Charmacy Pharmaceutical Co (HKSE:02289) Overvalued in 2026?

Based on GuruFocus' analysis, Charmacy Pharmaceutical Co stock appears to be undervalued. The current stock price of HK$5.50 is trading 34.4% below its estimated GF Value™ of HK$8.38. GuruFocus considers Charmacy Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for HKSE:02289:

  • Beneish M-Score: -2.79
  • GF Value™: HK$8.38 vs. price of HK$5.50 (34.4% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the HKSE:02289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Charmacy Pharmaceutical Co Business Description

Address No. 235, Song Shan North Road, Longhu District, Guangdong Province, Shantou, CHN, 515041
Charmacy Pharmaceutical Co Ltd operates within the pharmaceutical distribution industry, with a primary focus on the distribution of pharmaceutical products. The principal business activities encompass the wholesale of pharmaceuticals and related services, along with road transportation and cargo warehousing. The company's distribution network covers Southern China and surrounding areas including Fujian province. All the group's operations are located in China.
76GF Score

Get the complete analysis for HKSE:02289

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$5.50
Price
HK$8.38
GF Value